Journal
Blood
Publication Date
2-13-2025
Volume
145
Issue
7
First Page
708
Last Page
719
Document Type
Open Access Publication
DOI
10.1182/blood.2024025454
Rights and Permissions
Sehn LH, Bartlett NL, Matasar MJ, Schuster SJ, Assouline SE, Giri P, Kuruvilla J, Shadman M, Cheah CY, Dietrich S, Fay K, Ku M, Nastoupil LJ, Wei MC, Yin S, To I, Kaufman D, Kwan A, Penuel E, Bolen CR, Budde LE. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. Blood. 2025 Feb 13;145(7):708-719. doi: 10.1182/blood.2024025454. © 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Recommended Citation
Sehn, Laurie H; Bartlett, Nancy L; and et al., "Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies." Blood. 145, 7. 708 - 719. (2025).
https://digitalcommons.wustl.edu/oa_4/4973
Additional Links
Supplemental material is available for this article at publisher site.
